Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AbCellera

- PMLiVE

Lilly’s Trulicity scores CV reduction indication in the US

Approved for risk reduction in primary and secondary populations

- PMLiVE

US backs Sanofi’s ‘fast-track’ coronavirus vaccine

Development will tap into earlier work on the SARS virus

AstraZeneca AZ

AZ revenues rise, but it says coronavirus could hit 2020

Product sales up 12% to $23.57bn for the full-year

- PMLiVE

China’s BrightGene successfully copies Gilead’s coronavirus hopeful remdesivir

Raises concerns over patent exclusivity in the country

- PMLiVE

UPDATED: J&J expands US partnership for coronavirus treatments

Expands on exisiting alliance announced last week

- PMLiVE

Four more coronavirus cases confirmed in the UK

Secretary of State declares outbreak a “serious and imminent threat”

- PMLiVE

Double blow to amyloid drug hopes as Roche, Lilly trial fails

The two investigational candidates were unable to show benefit

- PMLiVE

Lilly launches migraine med Reyvow at $640 per eight-pill pack

Enters increasingly competitive market

- PMLiVE

GSK and Gilead join global efforts to tackle novel coronavirus

Confirmed cases rise to over 17,000 in China

- PMLiVE

UK confirms first cases of coronavirus as global concerns mount

Pharma industry steps up its efforts to develop therapeutics for infection

- PMLiVE

Lilly posts higher-than-expected profit as new drugs lift outlook

Sales boosted by growth of Trulicity and Taltz

- PMLiVE

J&J begins search for a coronavirus vaccine as confirmed cases rise

Death toll has now reached 170, with 7,711 confirmed cases in China

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links